Genetic profiling in acute myeloid leukaemia {box drawings light horizontal} where are we and what is its role in patient management

British Journal of Haematology

Volumn 160, Issue 3, 2013, Pages 303-320

  Ofran, Yishai ^a,b   Rowe, Jacob M ^a,b,c  

^a Department of Haematology and Bone Marrow Transplantation ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Acute myeloid leukaemia; Acute myeloid leukaemia classification; Genetic interaction; Genetic profile

Indexed keywords

ANTHRACYCLINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; INTERLEUKIN 2 RECEPTOR ALPHA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MICRORNA; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CYTOGENETICS; DIAGNOSTIC VALUE; DNA MICROARRAY; DRUG MEGADOSE; GENE EXPRESSION PROFILING; GENE INTERACTION; GENETIC ANALYSIS; GENETIC PROFILING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MLL GENE; NONHUMAN; ONCOGENE; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; SURVIVAL PREDICTION; TANDEM REPEAT; TET2 GENE;

CHROMOSOME ABERRATIONS; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MUTATION; POINT-OF-CARE SYSTEMS; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872597896     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12135     Document Type: Review

References (127)

1. Agirre, X., Martinez- Climent, J.A., Odero, M.D. & Prosper, F. (2012) Epigenetic regulation of miRNA genes in acute leukemia. Leukemia, 26, 395-403.
2. Ahmad, E.I., Gawish, H.H., Al Azizi, N.M. & Elhefni, A.M. (2011) The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine. OncoTargets and Therapy, 4, 115-121.
3. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
4. Basecke, J., Whelan, J.T., Griesinger, F. & Bertrand, F.E. (2006) The MLL partial tandem duplication in acute myeloid leukaemia. British Journal of Haematology, 135, 438-449.
5. Becker, H., Marcucci, G., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Whitman, S.P., Paschka, P., Holland, K.B., Schwind, S., Wu, Y.Z., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Moore, J.O., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 116, 788-792.
6. Boissel, N., Leroy, H., Brethon, B., Philippe, N., de Botton, S., Auvrignon, A., Raffoux, E., Leblanc, T., Thomas, X., Hermine, O., Quesnel, B., Baruchel, A., Leverger, G., Dombret, H. & Preudhomme, C. (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 20, 965-970.
7. Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M.J., Larrayoz, M.J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., Hellstrom-Lindberg, E., Cazzola, M. & Wainscoat, J.S. (2010) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia, 24, 1062-1065.
8. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen- Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791-4797.
9. Bullinger, L., Dohner, K., Kranz, R., Stirner, C., Frohling, S., Scholl, C., Kim, Y.H., Schlenk, R.F., Tibshirani, R., Dohner, H. & Pollack, J.R. (2008) An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood, 111, 4490-4495.
10. Bullinger, L., Ehrich, M., Dohner, K., Schlenk, R.F., Dohner, H., Nelson, M.R. & van den Boom, D. (2010) Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood, 115, 636-642.
11. Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325-4336.
12. Care, R.S., Valk, P.J., Goodeve, A.C., Abu- Duhier, F.M., Geertsma- Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Lowenberg, B. & Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 775-777.
13. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.P., Godley, L.A., Li, W. & Goodell, M.A. (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44, 23-31.
14. Chen, Y., Costa, R.M.B., Love, N.R., Soto, X., Roth, M., Paredes, R. & Amaya, E. (2009) C/EBPα initiates primitive myelopoiesis in pluripotent embryonic cells. Blood, 114, 40-48.
15. Chevallier, P., Labopin, M., Turlure, P., Prebet, T., Pigneux, A., Hunault, M., Filanovsky, K., Cornillet-Lefebvre, P., Luquet, I., Lode, L., Richebourg, S., Blanchet, O., Gachard, N., Vey, N., Ifrah, N., Milpied, N., Harousseau, J.L., Bene, M.C., Mohty, M. & Delaunay, J. (2011) A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia, 25, 939-944.
16. Chou, W.C., Huang, H.H., Hou, H.A., Chen, C.Y., Tang, J.L., Yao, M., Tsay, W., Ko, B.S., Wu, S.J., Huang, S.Y., Hsu, S.C., Chen, Y.C., Huang, Y.N., Chang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tseng, M.H., Huang, C.F. & Tien, H.F. (2010) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 116, 4086-4094.
17. Chou, W.C., Chou, S.C., Liu, C.Y., Chen, C.Y., Hou, H.A., Kuo, Y.Y., Lee, M.C., Ko, B.S., Tang, J.L., Yao, M., Tsay, W., Wu, S.J., Huang, S.Y., Hsu, S.C., Chen, Y.C., Chang, Y.C., Kuo, K.T., Lee, F.Y., Liu, M.C., Liu, C.W., Tseng, M.H., Huang, C.F. & Tien, H.F. (2011) TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 118, 3803-3810.
18. Damm, F., Heuser, M., Morgan, M., Yun, H., Grosshennig, A., Gohring, G., Schlegelberger, B., Dohner, K., Ottmann, O., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A., Fiedler, W., Kirchner, H., Dohner, H., Heil, G., Ganser, A. & Krauter, J. (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology, 28, 578-585.
19. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., Marks, K.M., Prins, R.M., Ward, P.S., Yen, K.E., Liau, L.M., Rabinowitz, J.D., Cantley, L.C., Thompson, C.B., Vander Heiden, M.G. & Su, S.M. (2009) Cancer-associated IDH1 mutations prod-uce 2-hydroxyglutarate. Nature, 462, 739-744.
20. Davies, S.M., Rowe, J.M. & Appelbaum, F.R. (2008) Indications for hematopoietic cell transplantation in acute leukemia. Biology of Blood and Marrow Transplantation, 14, 154-164.
21. Dohner, K., Brown, J., Hehmann, U., Hetzel, C., Stewart, J., Lowther, G., Scholl, C., Frohling, S., Cuneo, A., Tsui, L.C., Lichter, P., Scherer, S.W. & Dohner, H. (1998) Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood, 92, 4031-4035.
22. Dohner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Frohling, S. & Dohner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-3746.
23. Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
24. van Dongen, J.J. & Orfao, A. (2012) EuroFlow: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia, 26, 1899-1907.
25. Ernst, T., Chase, A.J., Score, J., Hidalgo- Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., Hochhaus, A., Drexler, H.G., Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F.H. & Cross, N.C. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 42, 722-726.
26. Estey, E.H. (2011) Treatment of acute myeloid leukemia in the elderly. Haematologica, 96, 795-798.
27. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254-266.
28. Fathi, A.T. & Abdel-Wahab, O. (2012) Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Advances in Hematology, 2012, 469592.
29. Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. & Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 1249-1259.
30. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L. & Melnick, A. (2010a) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-567.
31. Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., Greally, J.M., Valk, P.J., Lowenberg, B., Delwel, R. & Melnick, A. (2010b) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 17, 13-27.
32. Gaidzik, V.I., Schlenk, R.F., Moschny, S., Becker, A., Bullinger, L., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Dohner, H. & Dohner, K. (2009) Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood, 113, 4505-4511.
33. Gaidzik, V.I., Bullinger, L., Schlenk, R.F., Zimmermann, A.S., Rock, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Spath, D., Kundgen, A., Schmidt- Wolf, I.G., Gotze, K., Nachbaur, D., Pfreundschuh, M., Horst, H.A., Dohner, H. & Dohner, K. (2011) RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. Journal of Clinical Oncology, 29, 1364-1372.
34. Gale, R.E., Green, C., Allen, C., Mead, A.J., Burnett, A.K., Hills, R.K. & Linch, D.C. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 111, 2776-2784.
35. Gentles, A.J., Plevritis, S.K., Majeti, R. & Alizadeh, A.A. (2010) Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA, 304, 2706-2715.
36. Gonen, M., Sun, Z., Figueroa, M.E., Patel, J.P., Abdel-Wahab, O., Racevskis, J., Ketterling, R.P., Fernandez, H., Rowe, J.M., Tallman, M.S., Melnick, A., Levine, R.L. & Paietta, E. (2012) CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 120, 2297-2306.
37. Green, C.L., Evans, C.M., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2010) The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood, 116, 2779-2782.
38. Green, C.L., Evans, C.M., Zhao, L., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2011) The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 118, 409-412.
39. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.
40. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., Wheatley, K., Burnett, A.K. & Goldstone, A.H. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312-1320.
41. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010a) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-365.
42. Grimwade, D., Vyas, P. & Freeman, S. (2010b) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656-663.
43. Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., Dang, L., Fantin, V.R. & Mak, T.W. (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine, 207, 339-344.
44. Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.M., Staib, P., Serve, H., Kreuzer, K.A., Kern, W., Haferlach, T. & Haferlach, C. (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood, 120, 2963-2972.
45. Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G.T., Bene, M.C., De Vos, J., Hernandez, J.M., Hofmann, W.K., Mills, K.I., Gilkes, A., Chiaretti, S., Shurtleff, S.A., Kipps, T.J., Rassenti, L.Z., Yeoh, A.E., Papenhausen, P.R., Liu, W.M., Williams, P.M. & Foa, R. (2010) Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 28, 2529-2537.
46. Haferlach, C., Alpermann, T., Schnittger, S., Kern, W., Chromik, J., Schmid, C., Pielken, H.J., Kreuzer, K.A., Hoffkes, H.G. & Haferlach, T. (2012a) Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood, 119, 2122-2125.
47. Haferlach, C., Kern, W., Schindela, S., Kohlmann, A., Alpermann, T., Schnittger, S. & Haferlach, T. (2012b) Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer, 51, 257-265.
48. Havelange, V., Stauffer, N., Heaphy, C.C., Volinia, S., Andreeff, M., Marcucci, G., Croce, C.M. & Garzon, R. (2011) Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer, 117, 4696-4706.
49. Heesch, S., Schlee, C., Neumann, M., Stroux, A., Kuhnl, A., Schwartz, S., Haferlach, T., Goekbuget, N., Hoelzer, D., Thiel, E., Hofmann, W.K. & Baldus, C.D. (2010) BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia, 24, 1429-1436.
50. van der Holt, B., Breems, D.A., Berna Beverloo, H., van den Berg, E., Burnett, A.K., Sonneveld, P. & Lowenberg, B. (2007) Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. British Journal of Haematology, 136, 96-105.
51. Illmer, T., Thiede, C., Fredersdorf, A., Stadler, S., Neubauer, A., Ehninger, G. & Schaich, M. (2005) Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clinical Cancer Research, 11, 3217-3224.
52. Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., Preudhomme, C., Ades, L., Fenaux, P. & Fontenay, M. (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 25, 1147-1152.
53. Jerez, A., Sugimoto, Y., Makishima, H., Verma, A., Jankowska, A.M., Przychodzen, B., Visconte, V., Tiu, R.V., O' Keefe, C.L., Mohamedali, A.M., Kulasekararaj, A.G., Pellagatti, A., McGraw, K., Muramatsu, H., Moliterno, A.R., Sekeres, M.A., McDevitt, M.A., Kojima, S., List, A., Boultwood, J., Mufti, G.J. & Maciejewski, J.P. (2012) Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood, 119, 6109-6117.
54. Kakizuka, A., Miller, W.H. Jr, Umesono, K., Warrell, R.P. Jr, Frankel, S.R., Murty, V.V., Dmitrovsky, E. & Evans, R.M. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66, 663-674.
55. Kayser, S., Zucknick, M., Dohner, K., Krauter, J., Kohne, C.H., Horst, H.A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Rummel, M., Germing, U., Gotze, K., Nachbaur, D., Schlegelberger, B., Gohring, G., Spath, D., Morlok, C., Teleanu, V., Ganser, A., Dohner, H. & Schlenk, R.F. (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood, 119, 551-558.
56. Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., Liu, X.S., Aravind, L., Agarwal, S., Maciejewski, J.P. & Rao, A. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468, 839-843.
57. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
58. Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. & Linch, D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 2393-2398.
59. Le Dieu, R., Taussig, D.C., Ramsay, A.G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A.M., Lister, T.A. & Gribben, J.G. (2009) Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood, 114, 3909-3916.
60. Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford- Shore, B.H., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D.E., Koboldt, D.C., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D., Hillier, L.W., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J.R., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W.D., Nagarajan, R., Walter, M.J., Link, D.C., Graubert, T.A., DiPersio, J.F. & Wilson, R.K. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456, 66-72.
61. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363, 2424-2433.
62. Lioumi, M. & Newell, D. (2010) CR-UK biomarker roadmaps. In: AACR Meeting Abstracts, Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development- Sep 27-30, 2010; Denver, CO, 2010: B33a. http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2010/1_Molecular_Diagnostics_Meeting/B33.
63. Lowenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., van Marwijk Kooy, M., Verdonck, L.F., Beck, J., Dohner, H., Gratwohl, A., Pabst, T. & Verhoef, G. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361, 1235-1248.
64. Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C.R., Khanin, R., Figueroa, M.E., Melnick, A., Wellen, K.E., O' Rourke, D.M., Berger, S.L., Chan, T.A., Levine, R.L., Mellinghoff, I.K. & Thompson, C.B. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 483, 474-478.
65. Marcucci, G., Maharry, K., Radmacher, M.D., Mrozek, K., Vukosavljevic, T., Paschka, P., Whitman, S.P., Langer, C., Baldus, C.D., Liu, C.G., Ruppert, A.S., Powell, B.L., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 26, 5078-5087.
66. Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrozek, K., Margeson, D., Holland, K.B., Whitman, S.P., Becker, H., Schwind, S., Metzeler, K.H., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 2348-2355.
67. Marcucci, G., Mrozek, K., Radmacher, M.D., Garzon, R. & Bloomfield, C.D. (2011) The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood, 117, 1121-1129.
68. Marcucci, G., Metzeler, K.H., Schwind, S., Becker, H., Maharry, K., Mrozek, K., Radmacher, M.D., Kohlschmidt, J., Nicolet, D., Whitman, S.P., Wu, Y.Z., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Moore, J.O., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology, 30, 742-750.
69. Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361, 1058-1066.
70. Margulies, M., Egholm, M., Altman, W.E., Attiya, S., Bader, J.S., Bemben, L.A., Berka, J., Braverman, M.S., Chen, Y.J., Chen, Z., Dewell, S.B., Du, L., Fierro, J.M., Gomes, X.V., Godwin, B.C., He, W., Helgesen, S., Ho, C.H., Irzyk, G.P., Jando, S.C., Alenquer, M.L., Jarvie, T.P., Jirage, K.B., Kim, J.B., Knight, J.R., Lanza, J.R., Leamon, J.H., Lefkowitz, S.M., Lei, M., Li, J., Lohman, K.L., Lu, H., Makhijani, V.B., McDade, K.E., McKenna, M.P., Myers, E.W., Nickerson, E., Nobile, J.R., Plant, R., Puc, B.P., Ronan, M.T., Roth, G.T., Sarkis, G.J., Simons, J.F., Simpson, J.W., Srinivasan, M., Tartaro, K.R., Tomasz, A., Vogt, K.A., Volkmer, G.A., Wang, S.H., Wang, Y., Weiner, M.P., Yu, P., Begley, R.F. & Rothberg, J.M. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature, 437, 376-380.
71. McDevitt, M.A. (2012) Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Seminars in Oncology, 39, 109-122.
72. Medeiros, B.C., Othus, M., Fang, M., Roulston, D. & Appelbaum, F.R. (2010) Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood, 116, 2224-2228.
73. Mendler, J.H., Maharry, K., Radmacher, M.D., Mrozek, K., Becker, H., Metzeler, K.H., Schwind, S., Whitman, S.P., Khalife, J., Kohlschmidt, J., Nicolet, D., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2012) RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of Clinical Oncology, 30, 3109-3118.
74. Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Becker, H., Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., Wu, Y.Z., Blum, W., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2011) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 29, 1373-1381.
75. Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., Delabesse, E., de Oliveira, M.P., Cave, H., Clappier, E., van Dongen, J.J., Balgobind, B.V., van den Heuvel- Eibrink, M.M., Beverloo, H.B., Panzer-Grumayer, R., Teigler-Schlegel, A., Harbott, J., Kjeldsen, E., Schnittger, S., Koehl, U., Gruhn, B., Heidenreich, O., Chan, L.C., Yip, S.F., Krzywinski, M., Eckert, C., Moricke, A., Schrappe, M., Alonso, C.N., Schafer, B.W., Krauter, J., Lee, D.A., Zur Stadt, U., Te Kronnie, G., Sutton, R., Izraeli, S., Trakhtenbrot, L., Lo Nigro, L., Tsaur, G., Fechina, L., Szczepanski, T., Strehl, S., Ilencikova, D., Molkentin, M., Burmeister, T., Dingermann, T., Klingebiel, T. & Marschalek, R. (2009) New insights to the MLL recombinome of acute leukemias. Leukemia, 23, 1490-1499.
76. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. & Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911-1918.
77. Nardi, V., Winkfield, K.M., Ok, C.Y., Niemierko, A., Kluk, M.J., Attar, E.C., Garcia-Manero, G., Wang, S.A. & Hasserjian, R.P. (2012) Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. Journal of Clinical Oncology, 30, 2340-2347.
78. Neubauer, A., Maharry, K., Mrozek, K., Thiede, C., Marcucci, G., Paschka, P., Mayer, R.J., Larson, R.A., Liu, E.T. & Bloomfield, C.D. (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 26, 4603-4609.
79. Nibourel, O., Kosmider, O., Cheok, M., Boissel, N., Renneville, A., Philippe, N., Dombret, H., Dreyfus, F., Quesnel, B., Geffroy, S., Quentin, S., Roche-Lestienne, C., Cayuela, J.M., Roumier, C., Fenaux, P., Vainchenker, W., Bernard, O.A., Soulier, J., Fontenay, M. & Preudhomme, C. (2010) Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 116, 1132-1135.
80. Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., van der Reijden, B.A. & Jansen, J.H. (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genetics, 42, 665-667.
81. O'Keefe, C., McDevitt, M.A. & Maciejewski, J.P. (2010) Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood, 115, 2731-2739.
82. Ostronoff, F., Othus, M., Ho, P.A., Kutny, M., Geraghty, D.E., Petersdorf, S.H., Godwin, J.E., Willman, C.L., Radich, J.P., Appelbaum, F.R., Stirewalt, D.L. & Meshinchi, S. (2012) Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia, Epub ahead of print. doi: 10.1038/leu.2012.168.
83. Park, S.H., Chi, H.S., Min, S.K., Park, B.G., Jang, S. & Park, C.J. (2011) Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leukemia Research, 35, 1376-1383.
84. Paschka, P., Marcucci, G., Ruppert, A.S., Mrozek, K., Chen, H., Kittles, R.A., Vukosavljevic, T., Perrotti, D., Vardiman, J.W., Carroll, A.J., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 24, 3904-3911.
85. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
86. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366, 1079-1089.
87. Perea, G., Lasa, A., Aventin, A., Domingo, A., Villamor, N., Queipo de Llano, M.P., Llorente, A., Junca, J., Palacios, C., Fernandez, C., Gallart, M., Font, L., Tormo, M., Florensa, L., Bargay, J., Marti, J.M., Vivancos, P., Torres, P., Berlanga, J.J., Badell, I., Brunet, S., Sierra, J. & Nomdedeu, J.F. (2006) Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia, 20, 87-94.
88. Perez-Garcia, A., Brunet, S., Berlanga, J.J., Tormo, M., Nomdedeu, J., Guardia, R., Ribera, J.M., Heras, I., Llorente, A., Hoyos, M., Esteve, J., Besalduch, J., Bueno, J., Sierra, J. & Gallardo, D. (2009) CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia, 23, 486-491.
89. Perrot, A., Luquet, I., Pigneux, A., Mugneret, F., Delaunay, J., Harousseau, J.L., Barin, C., Cahn, J.Y., Guardiola, P., Himberlin, C., Recher, C., Vey, N., Lioure, B., Ojeda-Uribe, M., Fegueux, N., Berthou, C., Randriamalala, E., Bene, M.C., Ifrah, N. & Witz, F. (2011) Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood, 118, 679-685.
90. Pollard, J.A., Alonzo, T.A., Gerbing, R.B., Ho, P.A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N.J., Becton, D., Chang, M., Weinstein, H.J., Hirsch, B., Raimondi, S.C., Heerema, N.A., Woods, W.G., Lange, B.J., Hurwitz, C., Arceci, R.J., Radich, J.P., Bernstein, I.D., Heinrich, M.C. & Meshinchi, S. (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood, 115, 2372-2379.
91. Pratcorona, M., Abbas, S., Sanders, M.A., Koenders, J.E., Kavelaars, F.G., Erpelinck- Verschueren, C.A., Zeilemakers, A., Lowenberg, B. & Valk, P.J. (2012) Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica, 97, 388-392.
92. Prebet, T., Boissel, N., Reutenauer, S., Thomas, X., Delaunay, J., Cahn, J.Y., Pigneux, A., Quesnel, B., Witz, F., Thepot, S., Ugo, V., Terre, C., Recher, C., Tavernier, E., Hunault, M., Esterni, B., Castaigne, S., Guilhot, F., Dombret, H. & Vey, N. (2009) Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. Journal of Clinical Oncology, 27, 4747-4753.
93. Prensner, J.R. & Chinnaiyan, A.M. (2011) Metabolism unhinged: IDH mutations in cancer. Nature Medicine, 17, 291-293.
94. Raaijmakers, M.H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J.A., Ebert, B.L., Al-Shahrour, F., Hasserjian, R.P., Scadden, E.O., Aung, Z., Matza, M., Merkenschlager, M., Lin, C., Rommens, J.M. & Scadden, D.T. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature, 464, 852-857.
95. Renneville, A., Boissel, N., Gachard, N., Naguib, D., Bastard, C., de Botton, S., Nibourel, O., Pautas, C., Reman, O., Thomas, X., Gardin, C., Terre, C., Castaigne, S., Preudhomme, C. & Dombret, H. (2009a) The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood, 113, 5090-5093.
96. Renneville, A., Boissel, N., Zurawski, V., Llopis, L., Biggio, V., Nibourel, O., Philippe, N., Thomas, X., Dombret, H. & Preudhomme, C. (2009b) Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer, 115, 3719-3727.
97. Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Helevaut, N., Gardin, C., Cayuela, J.M., Hayette, S., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., Botton, S., Revel, T., Terre, C., Fenaux, P., Thomas, X., Castaigne, S., Dombret, H. & Preudhomme, C. (2012) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 26, 1247-1254.
98. Ribeiro, A.F., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M.E., Zeilemaker, A., Melnick, A., Lowenberg, B., Valk, P.J. & Delwel, R. (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood, 119, 5824-5831.
99. Rollig, C., Thiede, C., Gramatzki, M., Aulitzky, W., Bodenstein, H., Bornhauser, M., Platzbecker, U., Stuhlmann, R., Schuler, U., Soucek, S., Kramer, M., Mohr, B., Oelschlaegel, U., Stolzel, F., von Bonin, M., Wermke, M., Wandt, H., Ehninger, G. & Schaich, M. (2010) A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood, 116, 971-978.
100. Rollig, C., Bornhauser, M., Thiede, C., Taube, F., Kramer, M., Mohr, B., Aulitzky, W., Bodenstein, H., Tischler, H.J., Stuhlmann, R., Schuler, U., Stolzel, F., von Bonin, M., Wandt, H., Schafer-Eckart, K., Schaich, M. & Ehninger, G. (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. Journal of Clinical Oncology, 29, 2758-2765.
101. Rowe, J.M., Neuberg, D., Friedenberg, W., Bennett, J.M., Paietta, E., Makary, A.Z., Liesveld, J.L., Abboud, C.N., Dewald, G., Hayes, F.A., Tallman, M.S. & Wiernik, P.H. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood, 103, 479-485.
102. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909-1918.
103. Schnittger, S., Wormann, B., Hiddemann, W. & Griesinger, F. (1998) Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood, 92, 1728-1734.
104. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
105. Schnittger, S., Kohl, T.M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K. & Schoch, C. (2006) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood, 107, 1791-1799.
106. Schoch, C., Schnittger, S., Klaus, M., Kern, W., Hiddemann, W. & Haferlach, T. (2003) AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood, 102, 2395-2402.
107. Shlush, L.I., Chapal-Ilani, N., Adar, R., Pery, N., Maruvka, Y., Spiro, A., Shouval, R., Rowe, J.M., Tzukerman, M., Bercovich, D., Izraeli, S., Marcucci, G., Bloomfield, C.D., Zuckerman, T., Skorecki, K. & Shapiro, E. (2012) Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. Blood, 120, 603-612.
108. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 4075-4083.
109. Stolzel, F., Pfirrmann, M., Aulitzky, W.E., Kaufmann, M., Bodenstein, H., Bornhauser, M., Rollig, C., Kramer, M., Mohr, B., Oelschlagel, U., Schmitz, N., Soucek, S., Thiede, C., Ehninger, G. & Schaich, M. (2011) Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia, 25, 420-428.
110. Tang, J.L., Hou, H.A., Chen, C.Y., Liu, C.Y., Chou, W.C., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Yao, M., Huang, S.Y., Ko, B.S., Hsu, S.C., Wu, S.J., Tsay, W., Chen, Y.C., Lin, L.I. & Tien, H.F. (2009) AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood, 114, 5352-5361.
111. Thiede, C. (2012) Impact of mutational analysis in acute myeloid leukemia. Hematology Education: The Education Program For The Annual Congress of the European Hematology Association, 6, 33-40.
112. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
113. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M. & Ehninger, G. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011-4020.
114. Thol, F., Damm, F., Ludeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Gohring, G., Schlegelberger, B., Hoelzer, D., Lubbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A. & Heuser, M. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of Clinical Oncology, 29, 2889-2896.
115. Trowbridge, J.J. & Orkin, S.H. (2012) Dnmt3a silences hematopoietic stem cell self-renewal. Nature Genetics, 44, 13-14.
116. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
117. Virappane, P., Gale, R., Hills, R., Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., Burnett, A., Linch, D., Bonnet, D., Lister, T.A. & Fitzgibbon, J. (2008) Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 26, 5429-5435.
118. Wagner, K., Damm, F., Gohring, G., Gorlich, K., Heuser, M., Schafer, I., Ottmann, O., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A.A., Fiedler, W., Kirchner, H.H., Brugger, W., Zucknick, M., Schlegelberger, B., Heil, G., Ganser, A. & Krauter, J. (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Journal of Clinical Oncology, 28, 2356-2364.
119. Wakita, S., Yamaguchi, H., Miyake, K., Mitamura, Y., Kosaka, F., Dan, K. & Inokuchi, K. (2011) Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia, 25, 1423-1432.
120. Wilop, S., Fernandez, A.F., Jost, E., Herman, J.G., Brummendorf, T.H., Esteller, M. & Galm, O. (2011) Array-based DNA methylation profiling in acute myeloid leukaemia. British Journal of Haematology, 155, 65-72.
121. Wilson, C.S., Davidson, G.S., Martin, S.B., Andries, E., Potter, J., Harvey, R., Ar, K., Xu, Y., Kopecky, K.J., Ankerst, D.P., Gundacker, H., Slovak, M.L., Mosquera-Caro, M., Chen, I.M., Stirewalt, D.L., Murphy, M., Schultz, F.A., Kang, H., Wang, X., Radich, J.P., Appelbaum, F.R., Atlas, S.R., Godwin, J. & Willman, C.L. (2006) Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood, 108, 685-696.
122. Wouters, B.J., Lowenberg, B. & Delwel, R. (2009a) A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood, 113, 291-298.
123. Wouters, B.J., Lowenberg, B., Erpelinck- Verschueren, C.A., van Putten, W.L., Valk, P.J. & Delwel, R. (2009b) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood, 113, 3088-3091.
124. Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. & Bigner, D.D. (2009) IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 360, 765-773.
125. Yanada, M., Kurosawa, S., Yamaguchi, T., Yamashita, T., Moriuchi, Y., Ago, H., Takeuchi, J., Nakamae, H., Taguchi, J., Sakura, T., Takamatsu, Y., Waki, F., Yokoyama, H., Watanabe, M., Emi, N. & Fukuda, T. (2012) Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica, 97, 915-918.
126. Yin, J.A., O' Brien, M.A., Hills, R.K., Daly, S.B., Wheatley, K. & Burnett, A.K. (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood, 120, 2826-2835.
127. Zhang, S.J., Rampal, R., Manshouri, T., Patel, J., Mensah, N., Kayserian, A., Hricik, T., Heguy, A., Hedvat, C., Gonen, M., Kantarjian, H., Levine, R.L., Abdel-Wahab, O. & Verstovsek, S. (2012) Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood, 119, 4480-4485.